SA Grover, L Coupal, H Zowall, CM … - Diabetes Care, 2001 - Am Diabetes Assoc OBJECTIVE— Epidemiological studies have shown that the risk of myocardial
infarction (MI) in diabetic patients without cardiovascular disease (CVD) is
comparable to the risk of MI in patients with CVD. We used a validated ... Cited by 76 - Related articles - BL Direct - All 12 versions
B Jönsson, JR Cook, TR Pedersen - Diabetologia, 1999 - Springer Diabetes is a major source of morbidity, mortality and medical costs. It has
been estimated that nearly 15% of national health care expenditures in the USA
is spent on treating patients with diabetes [1]. Patients with diabetes ... Cited by 85 - Related articles - BL Direct - All 3 versions
- ►ahajournals.org SA Grover, L Coupal, H Zowall, M Dorais - Circulation, 2000 - Am Heart Assoc Methods and Results—The model estimates were compared with the Scandinavian
Simvastatin Survival Study (4S) and used to estimate the long-term costs and
benefits of treatment with simvastatin. Simulations were performed for men ... Cited by 69 - Related articles - BL Direct - All 10 versions
MW Russell, DM Huse, JD Miller, DF Kraemer … - The Canadian journal of clinical pharmacology= …, 2001 - ncbi.nlm.nih.gov OBJECTIVE: To assess the cost effectiveness of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitor therapy, particularly atorvastatin, in
primary and secondary prevention of coronary artery disease (CAD) in ... Cited by 25 - Related articles - BL Direct - All 4 versions
M Brandle, MB Davidson, DL Schriger, B … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—There are ∼8.2 million Americans with diabetes, LDL cholesterol
levels ≥100 mg/dl, and no clinical evidence of cardiovascular disease. Each
year, statin therapy could prevent ∼71,000 major coronary events in this ... Cited by 40 - Related articles - BL Direct - All 6 versions
- ►health-economics.ca [PDF] SA Grover, L Coupal, S Paquet, H Zowall - Archives of Internal Medicine, 1999 - Am Med Assoc Methods A validated model based on data from the Lipid Research Clinics cohort
was used to estimate the benefits and cost-effectiveness of lipid modification
with 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) ... Cited by 71 - Related articles - BL Direct - All 6 versions
SA Grover, L Coupal, H Zowall, TW Weiss, … - The American journal of medicine, 2003 - Elsevier We estimated the number of adults (ages 30 to 74 years) requiring lipid therapy
using data from the third National Health and Nutrition Examination Survey and
current lipid treatment guidelines. Using the Cardiovascular Life ... Cited by 5 - Related articles - All 5 versions
WSB Treated - clinemetrica.com Background—The objective of this study was to estimate the long-term costs and
benefits of treating hyperlipidemia among diabetic patients with and without
known cardiovascular disease after validating the Cardiovascular Life ... Related articles - View as HTML - All 2 versions
J Tsevat, KM Kuntz, EJ Orav, MC Weinstein, … - American Heart Journal, 2001 - Elsevier Background The objective of this study was to assess the cost-effectiveness of
pravastatin therapy in survivors of myocardial infarction with average
cholesterol levels. Methods We performed a cost-effectiveness analysis ... Cited by 68 - Related articles - BL Direct - All 9 versions
- ►adisonline.com [PDF] PK Schadlich, JG Brecht, B Rangoonwala, E … - Pharmacoeconomics, 2004 - ingentaconnect.com Page 1. Pharmacoeconomics 2004; 22 (15): 955-973 O RIGINAL R ESEARCH A RTICLE
1170-7690/04/0015-0955/$31.00/0 2004 Adis Data Information BV. ... Cited by 15 - Related articles - BL Direct - All 7 versions
